DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday. The firm set a “hold” rating on the stock.

Several other brokerages have also recently issued reports on DBVT. JMP Securities raised their price objective on DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 31st. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Price Performance

Shares of DBVT opened at $0.92 on Monday. The stock has a market capitalization of $88.77 million, a price-to-earnings ratio of -1.10 and a beta of 0.68. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $3.70. The business’s 50 day simple moving average is $0.90 and its 200-day simple moving average is $1.22.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same quarter in the previous year, the business earned ($0.26) EPS. On average, sell-side analysts expect that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the quarter. DBV Technologies makes up about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent quarter. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.